17 results
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex … , accumulation of excess body fat and the establishment and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like … and perpetuation of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
of the obese state.
DCCR’s unique mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex
424B5
5vlnyl5j79ijvbvclju6
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
pxce2y 43i5
27 Sep 23
Prospectus supplement for primary offering
5:26pm
424B5
8blnjd1alj 0qana0rcq
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
f1ppm07 e7iy0
28 Mar 22
Prospectus supplement for primary offering
4:53pm
424B5
i9fulnzeavicd13r5f9g
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
0tyk ny68ulgoy
15 Nov 18
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018
4:02pm
S-1/A
73c8csa5az c2glmu
1 Jul 14
IPO registration (amended)
12:00am
- Prev
- 1
- Next